Tuesday, August 24, 2010

Roche teams up with Aileron Therapeutics to delivery new technology

The New York Times reports this morning that Roche will announce its investment in Aileron Therapeutics by paying $25 million now $1.1 billion at a later date. This new technology, called stapled peptides, works with stabilized form of peptides, a small protein, to deliver medicine inside cells for a variety of medical conditions. The companies main goals are to work in delivering drugs that will treat ailments in the following: cancer, viruses, inflammation, metabolism and the central nervous system. This delivery method is unique due to its ability to deliver potent amounts of medicine at the cellular level.

No comments:

Post a Comment